

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

05 FEB 25 PM 2: 16

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name

King & Spalding LLP

2. Address

Check if different than previously reported

1700 Pennsylvania Avenue, N.W.

3. Principal Place of Business (if different from line 2)

City: Washington

State/Zip (or Country): D.C. 20006

4. Contact Name

Theodore M. Hester

Telephone

202-626-2901

5. Senate ID#

21632-330

7. Client Name

UCB Pharma, Inc.

Self

6. House ID#

30750029

TYPE OF REPORT

8. Year 2004 Midyear (January 1- June 30) OR Year End (July 1 - Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____

11. No Lobbying Ac

INCOME OR EXPENSE - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more \$ 20,000

Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this report period were:

Less than \$10,000

\$10,000 or more \$ _____
Expenses (nearest \$

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

Method A. Reporting amounts using LDA definitio

Method B. Reporting amounts under section 6033(I Internal Revenue Code

Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____

Printed Name and Title _____

LD-2 (REV. 6/98)

Page __

Registrant Name King & Spalding LLP

Client Name UCB Pharma, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Pharmaceutical issues, including implementation of Medicare Prescription Drug benefit and treatment.


17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
William C. Talmadge	
Allison Kassir	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

The foreign entity has an interest in pharmaceutical issues, in implementation of the Medicare Prescription Drug benefit, and in epilepsy treatment.

Signature  2/14/15

